Data On 8 Novel Anticancer Compounds Unveiled By Taiho Pharmaceutical
11/08/2012
Taiho Pharmaceutical Co., Ltd. (HQ: Tokyo, President: Masayuki Kobayashi), the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies...
Seeking Better Drug Candidates To Inhibit Blood Clotting And Inflammation
11/08/2012
Scientists have identified a group of small molecules that interfere with the activity of a compound that initiates multiple steps in blood clotting, including those that lead to the obstruction of veins or arteries, a condition called thrombosis...
Gene Switch Important In Cancer Discovered
11/08/2012
Scientists at Karolinska Institutet in Sweden and the University of Helsinki in Finland have shown that the 'switches' that regulate the expression of genes play a major role in the development of cancer...
Inflammation Marker Linked To Increased Risk For Death From Cancer In Korean Men
11/08/2012
Measuring blood levels of high-sensitive C-reactive protein, an important marker of inflammation, in apparently cancer-free men could potentially help identify those at increased risk for death from cancer, in particular lung cancer, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research...
5,000 Combinations Of 100 Existing Cancer Drugs Tested To Find More Effective Treatments
11/08/2012
Scientists in the United States have tested all possible pairings of the 100 cancer drugs approved for use in patients in order to discover whether there are any combinations not tried previously that are effective in certain cancers...
In Advanced Solid Tumors, New Monoclonal Antibody Inhibits Tumor Growth In Phase I Clinical Trial
11/08/2012
A newly developed antibody targeting a signalling pathway that is frequently active in solid tumours has shown encouraging signs of efficacy in its first trial in humans, researchers reported at the 24th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland...
Sildenafil And Rapamycin Work Together To Improve Doxorubicin Cancer Treatment
11/08/2012
Combining cancer medication with a drug for erectile dysfunction and one for heart transplants helped kill cancer cells and protected the heart from damage, in a study presented at the American Heart Association's Scientific Sessions 2012. For decades, doxorubicin has been a powerful anti-cancer treatment for various human cancers, including breast, ovarian, colon and prostate...
Blood Marker Reveals Type 2 Diabetes Risk Years In Advance
11/08/2012
A new Swedish-led study has identified a blood marker that may show who is at risk of developing type 2 diabetes many years before the disease is typically diagnosed. Team leader Anders Rosengren, a researcher at the Lund University Diabetes Centre (LUDC), and colleagues, write about their findings in the 7 November issue of Cell Metabolism...
75 Percent Of Patients Taking Popular Blood-Thinners Are Given Wrong Dose
11/08/2012
Cardiology researchers at the Intermountain Medical Center Heart Institute have found that approximately 75 percent of patients taking two common blood-thinning drugs may be receiving the wrong dosage levels, according to a new study. This could put them at risk for serious problems like uncontrolled bleeding or developing blood clots...
Higher Dietary Glycemic Load Linked To Worse Colon Cancer Survival
11/07/2012
Researchers have identified a link between higher dietary glycemic load and total carbohydrate intake and increased risk of cancer recurrences or death among stage 3 colon cancer patients, a finding that suggests that diet and lifestyle modification can have a role in improving patient survival, according to a study published November 7 in the Journal of the National Cancer Institute...